Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments Strong balance sheet, bolstered …